Treatment of hodgkin lymphoma using an anti-pd-1 antibody
AssigneeBristol-Myers Squibb Company
InventorBenedetto FARSACI
Life of this patent
Estimating the term…
Abstract
This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody to a subject, wherein the subject has received at least one prior treatment for Hodgkin lymphoma.
Claims20
A method of treating a subject afflicted with a tumor derived from a Hodgkin lymphoma, comprising administering to the subject an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 receptor (PD-1) (“anti-PD-1 antibody”), wherein the subject was not responsive to a prior treatment comprising (i) an autologous stem cell therapy, and (ii) brentuximab vedotin.
Dependencies are inferred from the claim text.